Circadian Technologies Limited

Circadian Technologies Limited (ASX: CIR) is an Australian biotechnology company focused on the development of biologics-based therapies for the treatment of cancer and eye disease. Circadian owns an extensive patent portfolio covering targets (VEGF-C, VEGF-D, VEGFR-3) and drugs (VGX-100 and VGX-300) to modulate the processes of angiogenesis - the development of blood vessels within the body and lymphagiogenesis-the development of lymphatics in the human body.

Circadian's product pipeline includes biologics drugs targeting important mediators of angiogenesis and lymphangiogenesis. Circadian's lead development candidate, VGX-100, is a fully human antibody that inhibits the VEGF-C protein. VGX-100 is currently in Phase 1a and Phase 1b clinical trials in late stage cancer patients at 2 leading US cancer centres. These studies are being done under an IND. Phase 2 studies are expected to commence in H2 2013.

VGX-100 and VGX-300 are also being developed as agents to treat age related macular degeneration in patients non-responsive to anti-VEGF-A therapy. VEGF-C and VEGFR-3 have been shown to play a major role in retinal angiogenesis. VGX-100 and VGX-300 have been shown to be effective in animal models of back of the eye disease. They are currently in pre-clinical development with clinical development expected to commence by H1 2014.